🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Castrate Resistance Prostate Cancer

TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850Phase 1, Phase 221 sites📍 Miami📍 Miami📍 Atlanta Blue Earth Therapeutics Ltd · Tests: Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only) Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer NCT07002320Phase 1, Phase 24 sites📍 Bellinzona📍 Belfast📍 Cambridge Institute of Cancer Research, United Kingdom · Tests: SX-682, Apalutamide Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer NCT03819101Phase 330 sites📍 Olomouc📍 Villejuif📍 Besançon Gustave Roussy, Cancer Campus, Grand Paris · Tests: Acetylsalicylic acid, Atorvastatin Bipolar Androgen Therapy + Carboplatin in mCRPC NCT03522064Phase 21 site📍 Sydney St Vincent's Hospital, Sydney · Tests: Testosterone Enanthate 100 MG/ML Injectable Solution, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplati… A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer NCT04729114Phase 125 sites📍 Tucson📍 Anaheim📍 Santa Rosa Astellas Pharma Global Development, Inc. · Tests: PRL-02 injection, prednisone, dexamethasone, enzalutamide A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779Phase 3231 sites📍 Chandler📍 Gilbert📍 Glendale Pfizer · Tests: PF-06821497, Placebo, Enzalutamide Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537Phase 1, Phase 21 site📍 San Francisco Vadim S Koshkin · Tests: Abemaciclib, Lutetium Lu 177-PSMA-617 HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) NCT07441889Phase 1, Phase 21 site📍 Charlottesville University of Virginia · Tests: HER2 FPBMC Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer NCT06800313Phase 1, Phase 218 sites📍 Colorado Springs📍 Denver📍 New Haven Janssen Research & Development, LLC · Tests: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3 Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer NCT06927635Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Stereotactic Body Radiation Therapy (SBRT), Systemic therapy TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma NCT04969315Phase 1, Phase 22 sites📍 Los Angeles📍 Houston Portage Biotech · Tests: TT-10, TT-4 An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) NCT07206056Phase 1, Phase 235 sites📍 Denver📍 Jacksonville📍 Atlanta Novartis Pharmaceuticals · Tests: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium NCT07414940Phase 1, Phase 21 site📍 London University College, London · Tests: Actinium (225Ac) rhPSMA-10.1 Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer NCT06738303Phase 21 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Cabazitaxel and carboplatin, Lu-PSMA-617 Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial NCT06720532n/a1 site📍 Munich Hannah Schaefer · Tests: characterization of renal function., Handgrip strength test, Questionaires A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519Phase 1, Phase 214 sites📍 Phoenix📍 New Haven📍 Jacksonville 858 Therapeutics, Inc. · Tests: ETX-19477 Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) NCT06943495Phase 11 site📍 Québec Jean-Mathieu Beauregard · Tests: 177Lu-PSMA-617, 177Lu-PSMA-617 Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors NCT07226713Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: Pacritinib Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T NCT06134232Phase 231 sites📍 Tuscon📍 Duarte📍 Fresno Dendreon · Tests: Sipuleucel-T Injection Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC NCT07090148Phase 11 site📍 Madison University of Wisconsin, Madison · Tests: pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody Castrate Resistant Prostate Cancer Enhertu Therapy NCT06610825Phase 21 site📍 Washington D.C. Washington D.C. Veterans Affairs Medical Center · Tests: Enhertu Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer NCT05766371Phase 21 site📍 San Francisco University of California, San Francisco · Tests: Pembrolizumab, 177Lu-PSMA-617 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187Phase 110 sites📍 Denver📍 Orlando📍 Sarasota Dren Bio · Tests: DR-0202 Working Out M0 Bipolar Androgen Therapy NCT06594926Phase 212 sites📍 Garran📍 Albury📍 Darlinghurst Australian and New Zealand Urogenital and Prostate Cancer T… · Tests: Testosterone Enanthate Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer NCT06783127n/a2 sites📍 Naples📍 Trento Santa Chiara Hospital · Tests: Olaparib Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body NCT06470243Phase 3174 sites📍 Fayetteville📍 Rogers📍 Springdale SWOG Cancer Research Network · Tests: Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer NCT06702995Phase 1, Phase 22 sites📍 Jinan📍 Shanghai Evopoint Biosciences Inc. · Tests: XNW5004, enzalutamide A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272Phase 1, Phase 282 sites📍 Los Angeles📍 Orange📍 San Francisco Merck Sharp & Dohme LLC · Tests: Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy